ACULYS is a privately held biopharmaceutical company dedicated to the advancement and commercialization of cutting-edge therapeutics. Our main focus is on the field of CNS, with a strong commitment to enhancing the lives of individuals in Japan who are enduring severe neurologic conditions. Aculys is actively working on the development of a novel medication in Japan tailored for patients grappling with Narcolepsy and various sleep disorders. Additionally, we are continually seeking opportunities for the exploration of new breakthroughs to address the unmet needs of patients.